Open AccessEfficacy of a single fixed 131I dose of radioactive iodine for the treatment of hyperthyroidism
Author(s) -
Husain Taha Radhi
Publication year - 2019
Publication title -
endocrinology and disorders: open access
Language(s) - English
Resource type - Journals
ISSN - 2640-1045
DOI - 10.31579/2640-1045/045
Subject(s) - medicine , radioactive iodine , antithyroid drugs , thyroid , medical record , ablation , iodine , single center , nuclear medicine , graves' disease , materials science , metallurgy
A total of 135 patients were treated for hyperthyroidism with 131I 15 mCi radioiodine ablation. The therapeutic target was achieving hypothyroidism. Between January 2014 and December 2018, clinical records were reviewed and date was collected and reviewed for 135 patients with hyperthyroidism that were referred to the Nuclear Medicine Department at Salmaniya Medical Center, for radioactive iodine (RAI) thyroid gland ablation procedure for definitive treatment of hyperthyroidism. About 39.7% of our patients achieved response between 4-6 months out of which 35.7% of the patients showed response in the first 3 months. 21.4% of the patients took between 7-12 months to show response and only 3.2% responded after 12 months. The most significant response was hypothyroidism comprising of 94.4%. It is also worth mentioning that 4.0% of patients achieved euthyroidism and did not require any follow-up medication. Using fixed dose of RAI of 15mCi for treating various type of Hyperthyroidism, successful treatment with a single dose of RAI can be achieved in 92.7% of the patients, with first therapy failure rate in 7.3%, with few patients requiring additional doses of RAI.